U.S. Markets closed

Merck & Co.: Wall Street Analysts Are Mostly Positive in July

Daniel Collins
Merck & Co.: Wall Street Analysts Are Mostly Positive in July

In July, Japan’s Pharmaceuticals and Medical Devices Agency (or PMDA) approved Lynparza, manufactured by AstraZeneca (AZN) and Merck & Co. (MRK), for the treatment of individuals with unresectable or recurrent BRCA-mutated HER2 negative breast cancer who underwent prior chemotherapy.